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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMballoon and stent (BS), and atherectomy and balloon (AB) (B-29%, BS-27%, and AB-
31%). In repeat PVI, B and BS use were different from the initial PVI (B 39%, BS
17%, respectively p< 0.001), and AB use was not different (34%, p¼0.2). A network
plot of device use and change from initial to repeat procedure is shown (p< 0.001 for
pattern).Conclusions: In a contemporary PAD patient population, multiple PVI procedures
occur commonly, but the majority are procedures in a different vascular bed. Repeat
PVI in the same vessel occurs less often. Balloon angioplasty remains the dominant
procedure for both the initial or repeat LE PVI, either as stand-alone therapy or in
combination with stent or atherectomy.
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Background: Peripheral endovascular intervention (PVI) has changed the treat-
ment landscape for patients with PAD. The primary aim of this analysis is to
understand the trends and variation in PVI after changes in Medicare Coverage
Determination (MCD) in 2008 that affect professional and technical reimbursement
rates for PVI.
Methods: We utilized a 5% sample of Medicare beneﬁciaries from 2006 to 2011, and
patients were required to have a procedure code for revascularization and a diagnosis
code for PAD. Rates of revascularization were age- and sex-adjusted to the Medicare
fee-for-service population. Rates by treatment location, year, and physician specialty
were reported per 100,000 beneﬁciaries.
Results: 39,339 patients underwent revascularization for PAD and were included in
the analysis. The PVI rate increased from 4,986 in 2006 to 5,548 in 2011, while the
rate of surgical revascularization decreased from 1,562 in 2006 to 1,172 in 2011
[Panel A]. Surgeons (50%) and cardiologists (33%) performed the majority of PVI
[Panel B]. The rate of PVI performed in inpatient settings declined signiﬁcantly while
the rate of PVI performed in outpatient hospital settings and ofﬁce-based clinics
increased signiﬁcantly [Panel C]. The use of atherectomy increased 50-fold in ofﬁce-
based clinics since 2006.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/IliaConclusions: The overall rates of PVI increased by 10%, mostly performed by
surgeons and cardiologists. PVI and especially atherectomy use in outpatient set-
tings increased dramatically, highlighting possible unintended consequences of
coverage decisions and need for studies demonstrating beneﬁt for endovascular
technologies.
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Background: Endovascular approach to superﬁcial femoral artery (SFA) disease, the
most common cause of symptomatic PAD, remains fraught with high failure rates.
Newer devices including second-generation nitinol stents, drug-coated stents, drug-
coated balloons, covered stents, cryo-therapy, LASER and directional atherectomy,
have shown promising results. Clinical equipoise still persists regarding the optimal
selection of devices, largely attributable to the different inclusion criteria, study
population, length of lesions treated, deﬁnition of “patency” and “restenosis” and
follow-up methods in the pivotal trials.
Methods: A prospective protocol was developed. We performed a literature search
using PubMed from January 2006 – November 2013. Published articles including
endovascular interventions in SFA or popliteal arteries with reported 12-month “pri-
mary patency” or “binary restenosis” rates as endpoints were included.
Results: We identiﬁed 6024 patients in 61 trials reporting 12-month primary patency
rates in patients with femoropoliteal disease. Primary patency rates were (weighted
average) 78% for nitinol stents, 68.8% for Covered stents, 84% for Drug eluting
stents, 78.2% for DEB, 60.7% for cryoballoon, 51.1% for LASER atherectomy,
63.5% for directional atherectomy and 70.2% with a combination of endovascular
devices.
Conclusions: The most frequently used endovascular devices yielded various
12-month primary patency rates ranging from 51% to 85%. The increased variation in
inclusion criteria, length and complexity of lesions between studies does not allow
direct comparison between them. Larger randomized trials in speciﬁc patient pop-
ulations comparing those modalities is needed before we can make safe recommen-
dation of the superiority of one device over the other.
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Background: Case series where the use of optical coherence tomography (OCT)
greatly reduced or eliminated ﬂuoroscopy during the crossing of peripheral arterial
chronic total occlusions (CTOs) when using the Ocelot catheter (Avinger Inc, CA).
Methods: Fifteen patients, with sixteen lesions (n¼16) were successfully treated for
peripheral arterial CTOs between January 2013 and June 2013. Ocelot imaging
identiﬁes arterial structures to guide catheter crossing within the true lumen. By
placing the middle marker over arterial structures, the catheter tip is deﬂected in the
opposite direction towards atheroma (Figure 1). Time measurements were recorded for
diagnostic angiography, CTO crossing ﬂuoroscopy, and therapeutic ﬂuoroscopy
times.c and SFA B157
Vascular Procedure Outcome Payer Status
Adjusted* Odds
Ratio (95% CI) P Value
Bypass Surgery Death Medicare 1.40 (1.25-1.58) <0.001
Medicaid 0.82 (0.66-1.03) 0.94
Self-Pay 0.96 (0.68-1.35) 0.80
Endovascular
Treatment
Death Medicare 1.40 (1.26-1.55) <0.001
Medicaid 1.35 (1.13-1.62) 0.001
Self-Pay 1.31 (0.97-1.78) 0.08
Amputation Death Medicare 1.56 (1.39-1.74) <0.001
Medicaid 1.41 (1.20-1.66) <0.001
Self-Pay 1.11 (0.80-1.53) 0.54
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comResults: 100% of CTO’s in this series were crossed successfully via the true lumen
without the use of assist or re-entry devices. Mean CTO crossing ﬂuoroscopy time was
0.24 (14.4 seconds)  0.36 minutes using the Ocelot. Mean lesion length treated was
18.6 cm (18.63  8.58 cm) (Table 1). The treated lesions represented a spectrum of
calciﬁcation (mild/none¼2; moderate¼8; severe¼6).
Conclusions: The Ocelot catheter successfully crosses peripheral arterial chronic total
occlusions while eliminating, or signiﬁcantly reducing ﬂuoroscopic exposure and
associated contrast administration.
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Background: Chronic total occlusions (CTO) of the superﬁcial femoral artery (SFA)
are a challenging subset of lesions encountered in peripheral interventions. CTO’s of
the SFA are commonly crossed either with an intraluminal (IL) or re-entry device
assisted subintimal (SI) approach followed by stenting. Even though both these
techniques have a high immediate procedural success rate the long term outcomes of
each approach are not well studied.
Methods: We studied 215 patients (pts) (254 limbs) with obstructive SFA disease
treated with nitinol self-expanding stents of comparable lesion length; there were 205
(81%) limbs with CTO and 49 (19%) pts with non-CTO. We analyzed in-stent
restenosis (ISR) rates as well as demographic, procedural and laboratory character-







Age (years) 73.029.1 71.94 9.5 74.9 7.9
Mean stented length, mm 248.872.5 251.8199.2 280.091.9
GFR ml/min 52.322.3 62.6  20.5 58.621.9
Rutherford class 3 34(70%) 119(79%) 35(70%)
Rutheford class ‡4 15(30%) 32(21%) 15(30%)
Mean run-off score 5.12.5 3.92.8 3.92.9
Mean follow up period, mo 18.414.7 20.516.5 17.216.9
Mean duration to ISR, mo 13.311.8 13.09.2 13.310.4
ISR rate (%) 23(47%) 66(42%) 24(48%)Results: Baseline and procedural characteristcis of the studied groups presented in the
table. There were no signiﬁcant differences in the mean time to ISR, stented lesion
length, as well as other demographic, laboratory, and procedural parameters between
the studied groups except mean run-off score that was higher in non-CTO group (non
CTO vs. SI CTO, p¼0.05; non-CTO vs. IL CTO, p¼0.01). During follow up period of
19.2616.14 months, ISR was diagnosed in: 23 (47%) of pts of non-CTO group; 66
(42%) of IL CTO; and 24 (48%)pts of SI CTO group respectively. There were no
signiﬁcant differences in ISR rates between the groups (non-CTO vs. IL CTO,
p¼0.59; non-CTO vs. SI CTO, p¼0.9; IL CTO vs. SI CTO, p¼0.5).B158 JACC Vol 64/1Conclusions: In patients with long SFA lesions, we observed similar SFA ISR rates
between patients with and without CTO. Furthermore, in CTO group the long term
vessel patency was not affected by whether CTO was crossed using intraluminal or
subintimal approach.
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Background: Peripheral arterial disease (PAD) affects >8 million in US. Previous
studies suggested that patients with Medicare, Medicaid or no insurance received
poorer quality of care leading to worse outcomes in comparison to patients with
private insurance.
Methods: We analyzed all hospitalized PAD patients records from 01/2007 through
12/2011 in Nationwide Inpatient Sample (NIS) database. Temporal trends of pre-
senting diagnoses as well as vascular procedures performed (endovascular treatment,
bypass surgery and amputation) were analyzed. In addition, the unadjusted and
adjusted rates of adverse in-hospital outcomes (death, myocardial infarction, bleeding,
vascular complications, and acute renal failure (ARF)) were examined.
Results: The frequency of endovascular treatment for claudication from 2007 to 2011
decreased by 39.4%, while the annual incidence of bypass surgery and amputation
remained unchanged. Medicare (n¼731,264) and Medicaid (n¼72,050) patients were
more likely to undergo amputation than private insurance/HMO population
(n¼22,896), (adjusted OR 1.13, 95%CI 1.10-1.16, p< 0.001 and OR 1.24, 95%CI
1.20-1.29, p< 0.001, respectively). Both Medicare and Medicaid patients were less
likely to undergo bypass surgery (adjusted OR 0.82, 95%CI 0.81-0.84, p< 0.001 for
Medicare and OR 0.87, 95%CI 0.85-0.90, p< 0.001 for Medicaid), but more likely to
undergo endovascular procedures (adjusted OR 1.18, 95%CI 1.17-1.20, p< 0.001 for
Medicare and OR 1.03, 95%CI 1.01-1.06, p¼0.02 for Medicaid). Medicare and
Medicaid status was associated with worse in-hospital outcomes (Table).Conclusions: Medicare and Medicaid patients were more likely to undergo amputa-
tion and less likely to undergo vascular bypass surgery. Medicare or Medicaid status
was associated with worse in-hospital outcomes compared to private insurance/HMO
status.
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Background: Recent studies have reported presence of poor run-off vessels was
related to lower patency rates of SFA lesions, however it is still uncertain the role of
below-the-knee intervention (BTKI) for patency of SFA. The aim of this study was to
evaluate the impact of BTKI on the patency of SFA lesions after concomitant
treatment.
Methods: Percutaneous angioplasty with primary stenting at SFA was performed in
110 limbs (65 with BTKI) with 0 or 1 patent run-off vessel. Loss of patency was
deﬁned that aggravated ischemic symptoms with deterioration of calf-brachial index
by 0.15 from the maximum postprocedural level or stenosis by duplex ultrasound,1/Suppl B j September 13–17, 2014 j TCT Abstracts/Iliac and SFA
